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What’s already known about this topic?  
 Almost 70% of all leg ulcers have a venous component. Furthermore, up to 30% of 
venous leg ulcers (VLU’s) don't respond to compression alone, remain open after a 
year's treatment, needing an average of 51 treatment visits to heal. Therefore, 
adjunct therapies to compression are needed, which would improve healing 
outcomes. Exercise can form part of the therapeutic pathway, however, research 
evidence to determine whether exercise training has an effect on ulcer healing and 
QoL is limited, and further work is needed. 
 
What does this study add? 
 The findings support the feasibility and acceptability of supervised exercise training 
as an adjunct therapy for adults with VLU’s. Our preliminary data also support the 
potential effectiveness of exercise training in improving ulcer healing. An 
appropriately-powered, multi-centre trial is required to confirm the clinical and cost-
effectiveness of the intervention. 
 
Abstract 
Background:  Almost 70% of all leg ulcers have a venous component. Venous leg ulcers 
(VLU’s) are typically painful and heal slowly, resulting in an impaired quality of life (QoL), 
social isolation and reduced work productivity. Compression therapy offers high healing 
rates, however, improvements aren’t usually sustained. Exercise is a low-cost, low-risk, and 
effective strategy for improving physical and mental health. However, little is currently 
known about the feasibility and efficacy of supervised exercise training used in combination 
with compression therapy in this patient group. 
 
Objectives: To assess the feasibility of a 12-week supervised exercise programme combining 
aerobic, resistance and flexibility exercises as an adjunct therapy to compression in patients 
with VLU’s.  
 
Methods: This was a two-centre, two-arm, parallel-group, randomised feasibility trial. 
Thirty-nine patients with venous ulcers were recruited and randomised 1:1 either to 
exercise (3 sessions per week) and compression therapy or compression only. 
Progress/success criteria included exercise attendance rate, loss to follow-up and patients’ 
preference. Baseline assessments were repeated at 12 weeks, 6 months and 1 year 
following baseline, with healing rate and time, ulcer recurrence and infection incidents also 
being documented. Intervention and healthcare utilisation costs were calculated. 
Qualitative data was collected to assess participants' experiences.  
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Results: Overall, 72% of the exercise group participants attended all scheduled exercise 
sessions. No serious adverse events, and only two exercise-related adverse events (e.g., 
increased ulcer discharge) were reported. Loss to follow-up was 5%. At 12-months median 
ulcer healing time was lower in the exercise group (13 vs 34.7 weeks). Total NHS costs were 
calculated as £813.27 for the exercise and £2,298.57 for the control group.  
 
Conclusions: Our findings support the feasibility and acceptability of both the supervised 
exercise programme in conjunction with compression therapy and the study procedures. 
The next step will be the design and implementation of an appropriately-powered, multi-
centre trial. 
 
Introduction 
Almost 70% of all leg ulcers have a venous component.1 Occurrence of venous leg ulcers 
(VLU’s) increases with age, with the annual UK prevalence in those over 65 years being 
estimated at about 3%.2 VLU’s arise from venous valve incompetence and calf muscle pump 
insufficiency, which leads to venous stasis and hypertension. This results in microcirculatory 
changes and localised tissue ischaemia.3,4 The natural history of VLU’s is of a continuous 
cycle of healing and breakdown over decades5: VLU’s are typically painful and heal slowly, 
resulting in an impaired quality of life (QoL), social isolation and reduced work productivity.6 
Treatment of this major health problem results in a considerable cost to the National Health 
Service (NHS): each ulcer costs up to £1,981 per year7 and estimated total healthcare costs 
total between £198-£400 million per year8,9, with 65% of those occurring in the 
community.10 
Lower-limb compression therapy is an established first-line therapy for VLU’s11, with 
approximately 50% of VLUs closing within 24 weeks.10 Nevertheless, recurrence rates 
remain high (up to 56% within 4 years12). Furthermore, up to 30% of VLU’s don't respond to 
compression alone11, remain open after a year's treatment 13, needing an average of 51 
treatment visits to heal.10 Therefore, it is important to develop adjunct therapies to 
compression, which would improve healing outcomes.  
Lifestyle factors, including nutrition, exercise and smoking, are mentioned in guidelines on 
the management of VLU’s14, but receive relatively little emphasis. Exercise training might 
enhance ulcer healing and other aspects of health and is routinely prescribed for other 
cardiovascular disease (e.g., peripheral arterial disease15 and coronary artery disease16). In 
patients with VLU's, supervised calf muscle exercise has been shown to increase calf muscle 
pump function and improve lower-limb haemodynamics17,18, as well as mobility and QoL.19-
21 A recent systematic review suggested further research to determine whether exercise 
training has an effect on ulcer healing and QoL.22 
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Our team recently completed “FISCU”, (Feasibility of Implementing Supervised exercise 
training alongside Compression therapy in people with venous Ulceration - an NIHR-funded 
study; PB-PG-0213-30029)5 to assess the feasibility of a 12-week supervised exercise 
programme combining aerobic, resistance and flexibility exercises as an adjunct therapy to 
compression in patients with VLU’s. We report on rates of screening, eligibility, recruitment, 
retention, outcome completion, exercise adherence, and adverse events. We also report on 
reasons for exclusion and non-consent, sample characteristics, the distribution and 
completeness of potential primary outcomes as well as providing information on 
preliminary data on effectiveness and health care resource use. 
 
Methods  
A full description of methods is available in our previously published protocol paper.5 The 
study was a two-arm, parallel-group, randomised controlled feasibility trial conducted in 
two U.K. sites (Lincoln and Sheffield). Ethics approval was granted by the NHS National 
Research Ethics Service, Yorkshire and the Humber (Sheffield) Committee (14/YH/0091), and 
all participants provided written informed consent prior to enrolment. The trial was 
prospectively registered (Current Controlled Trials ISRCTN10205425). 
 
Participants  
Participants were recruited from community nursing and tissue viability teams or services, 
community and outpatient leg ulcer clinics, and newspaper advertisement. Inclusion and 
exclusion criteria are given in Table 1.  
 
Randomisation, allocation concealment and blinding  
Following baseline assessments, participants were randomly assigned 1:1 to an intervention 
group or a control group. Participants were stratified by ulcer size (maximum ulcer diameter 
1 – 3 cm or >3 cm in any direction). Outcome assessors were blinded to group allocation.  
 
Interventions 
All participants received standard compression therapy directed by experienced tissue-
viability nurses, following standard local practice. Patients were reviewed in clinics as 
considered clinically necessary, with no interference by the study team. 
 
Participants randomised in the exercise group were invited to attend three sessions of 
supervised exercise each week for 12 weeks (total of 36 sessions) at one of the two study 
exercise training facilities (Sheffield Hallam University and University of Lincoln). For details 
on the exercise components see Online Supplement 1. 
 
Study schedule and assessments 
In Visit 1, after written informed consent has been obtained and eligibility confirmed (which 
included a medical examination), the following baseline measurements were recorded at 
one of the two research centres (Sheffield Hallam University, University of Lincoln): 
-Demographic data, including age, sex, and socioeconomic status. 
-Clinical history, current medications, stature, body mass, ankle and calf circumference. 
-Ulcer size. 
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-ABPI: A Doppler-determined measurement of ABPI was performed according to the 
procedures of Aboyans et al.23, unless a reading <3 months old could be obtained from 
clinical records, following patient’s consent. 
-Baseline exercise history. 
-Health-related QoL questionnaires: EQ-5D-5L24,25 and VEINES-QOL.26 
-Lower-limb cutaneous microvascular function (methods27, 28 and results reported 
elsewhere). 
-Physical fitness, using 3 items from the Senior Fitness Test (6-minute walking test, chair sit 
and reach, chair sit and stand29) and ankle range of motion assessed using a bi-plane ankle 
goniometer. 
All participants were given a resource use diary to complete at home for the duration of the 
study (to conduct Health Economics’ analysis). 
Participants were then randomised to one of the two groups, as described above.  
At 12 weeks and 12 months, participants had the following measures and tests repeated: 
physical fitness, microvascular function, ulcer-related clinical data (size, status and 
recurrence) and medications, body mass and health-related QoL questionnaires. A copy of 
the resource use diary was also taken. A postal assessment involving the completion of 
health-related QoL questionnaires was also undertaken at 6 months.  
 
Feasibility and acceptability outcomes 
Recruitment rates were measured as rate of invited participants who are eligible and 
consenting. Acceptability of allocation was assessed by examining reasons for dropout in 
discontinuing participants and comparing attrition rates between the two study groups. 
Suitability of measurement procedures was evaluated by completion rates and reasons for 
missing data. Attrition rate was established as discontinuation of intervention and loss to 
follow-up measurement for all conditions. The acceptability of the exercise programmes 
was assessed by using session attendance and compliance data and participant feedback via 
one-to-one semi-structured interviews conducted with a sub-group of participants after the 
3-month follow-up visit (see 5; detailed analysis will be presented elsewhere). The safety of 
exercise training was also assessed by exploring reasons for dropout from the exercise 
programme and the number and type of adverse events that occurred in each group. 
 
Sample size  
Sample size calculation (see Online Supplement 1) was based on willingness for 
randomisation and aimed to recruit 80 participants within an 18-month recruitment period. 
 
Data analysis 
All analyses were conducted on intention to treat basis (ITT), conducted in SPSS version 24 
(IBM, USA). Missing data were reported by trial arm with description of underlying reasons.  
Baseline 
Summary tables report all baseline variables, clinical, fitness and patient-reported outcome 
variables.  Continuous variables were summarised with descriptive statistics.  Frequency 
counts and percentages were provided for categorical data.  
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Feasibility and acceptability  
For success criteria see Table 2. Outcomes used to assess the feasibility and acceptability of 
key trial parameters were rates of eligibility, recruitment, retention, outcome completion, 
exercise adherence, and adverse events.5 Group preference, reasons for exclusion and non-
consent, sample characteristics and the distribution of potential primary outcomes are 
presented.   
Clinical, fitness and patient-reported outcomes 
Descriptive statistics are presented for clinical, fitness and patient-reported outcomes at 
each time point.   
Economic evaluation  
A prospective economic evaluation was rehearsed to develop and refine the methods for a 
subsequent definitive trial (see Online Supplement 2).   
 
Results 
Figure 1 shows the flow of participants through the trial. Recruitment took place between 
July 2014 and May 2016, with all follow-up data collection completed by May 2017. The trial 
was extended for 3 months to allow extra recruitment time. 
  
Screening, eligibility and recruitment 
A summary of feasibility and acceptability data is presented in Table 3. All success criteria 
were met (e.g., 72% of participants completed all exercise sessions, loss to follow-up was 
5%, patients’ preference to the exercise group was 44%, while median ulcer healing time 
was chosen as the primary outcome for the definitive trial). Of 514 patients screened for 
participation, 109 met eligibility criteria and 39 (24 male, 15 female) were recruited, giving 
eligibility and recruitment rates of 21% and 36%, respectively. Sites 1 and 2 recruited 38 and 
1 participants, respectively. Reasons for non-consent and exclusion are shown in Figure 1.  
 
Group allocation, group preference and participant characteristics 
Eighteen participants were allocated to exercise and 21 to usual care. Seventeen (69%) of 27 
participants expressed a preference for exercise (12 expressed no preference). Participant 
characteristics at baseline are shown in Table 4; the groups were well balanced for most 
variables except QoL. 
 
Retention 
Retention rate was 95%. Two of 39 participants formally left the study; one from the 
exercise group for ulcer pain before the 3-month assessment, one control group for non-
ulcer related health reasons before the 6-month assessment. All others completed all 
assessment sessions. Five participants withdrew from exercise training due to family 
commitments and non-ulcer related health reasons. 
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Exercise attendance and safety data  
Of the 18 exercise participants, 13 (72%) completed all sessions, overall session completion 
rate of 79% (512/648). No bandage slippage/misplacement was detected during exercise 
sessions. We observed two exercise-related adverse events (both excessive discharge from 
the ulcer). Actions taken included the removal of resistance exercises and postponement of 
exercise sessions. 
 
Physical function and body mass 
Participants in the exercise group showed higher mean values at all 3 months in all tests 
(Table 5). Results stabilised at 12 months at all tests except plantar flexion. The reduction in 
weight was modest for the exercise group in relation to the baseline [(103.9 (24) at baseline 
vs 99.8 (28.4) at 12 months]. In contrast there was an increase in weight in the control 
group [(102.6 (25.6) vs 105.7 (25.2) at 12 months]. 
 
Ulcer related data 
Median ulcer size was similar at 12 months (Table 6), but healing rate was higher in the 
intervention group (83% vs 60%), with shorter median ulcer healing time (13 (3.9 to 52) vs 
34.7 weeks (4.3 to 52)). Recurrence rates were low in both groups (2 intervention vs 1 
control). 
 
Health-related QoL 
Participants in the intervention group started the study with a higher EQ5D utility score than 
the control group (Table 7; 0.8022 (0.17) vs 06010 (0.35)). This difference was maintained 
throughout the study. Similar difference was observed with EQ-Visual Analogue Scale, 
VEINES-QOL (overall score and symptom score) and pain score, although for VEINES-QOL 
and pain score the difference between groups was increased from 3 months onwards. 
 
Health Economic data 
There was no missing data for procedure costs. Mean cost per participant was £610.22, 
including staff time, room hire and patient reimbursement. Total NHS costs (based on NHS 
National Tariff Schedules and calculated based on visits and usage of NHS resources) were 
calculated as £813.27 for the exercise and £2,298.57 for the control group.  
  
Personal costs were calculated using a diary with “out of pocket” expenses being estimated 
at £113.63 and £174.58 for the exercise and control group respectively. 
 
The “per patient” cost-savings to NHS from the exercise intervention was £875.08. Similarly, 
the “per patient” less “out of pocket” expenses to participants, as a result of participation in 
exercise intervention was £60.95. The combined per “per patient” total cost-savings was 
£936.03 (Table 8; Online Supplement 2). 
 
Discussion 
Our study successfully assessed a series of feasibility study aspects, including recruitment, 
baseline and follow-up measurements, as well as the feasibility and preliminary 
effectiveness of a supervised exercised programme for people with venous leg ulcers. Our 
main finding was that the study procedures were feasible and acceptable. 
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The feasibility and acceptability of using a supervised exercise regime as an adjunct therapy 
to compression therapy, had been an area of uncertainty prior to this study. Indeed, during 
the preliminary study stages, such a notion was met with scepticism by some clinicians and 
patients, who believed that exercise may be either inappropriate or harmful and may delay 
rather than promote healing - an attitude that has been documented in the literature as 
well.30,31 Nevertheless, the majority of the eligible patients had a positive attitude towards 
undertaking exercise in addition to following a therapeutic pathway based on compression 
therapy. This was irrespective of whether they consented to take part and reasons for non-
participation will help make the programme more accessible (i.e., by choosing appropriate 
venues).  Our feasibility data show few adverse events, with no bandage misplacement or 
slippage incidents, one of the biggest concerns of collaborating clinicians.  
 
Exercise attendance was 79% with 72% completing all sessions.  This is high considering that 
many participants were old, frail and had no previous exercise experience. This was 
achieved without employing any specific adherence-enhancing components or provision of 
behavioural change support, which could have potentially improved attendance rates and 
the effect of the intervention even further.32 This suggests a great interest and self-
motivation from our participants, which will be a decisive factor for the success of a 
definitive trial and any wider roll-out of the intervention. Despite our success however, it is 
our plan to incorporate cognitive-behavioural strategies as part of any future trial to 
optimise exercise adherence and increase any potential, positive effect.   
 
In respect to practicality our intervention was primarily delivered within a university setting, 
at some distance from the clinics that our participants were treated. The high attendance 
rate, suggests that this didn’t have a negative impact on the outcome, although it may have 
impacted recruitment rate. Recruitment rate may be improved in the definitive trial, where 
12-week exercise referral schemes33 will be utilised for the intervention delivery. Delivery 
with an option of times in community-based venues increases accessibility but comes with a 
number of challenges (as adherence and success varies) 34, recent research suggests that 
these schemes can offer QoL and physical activity gains.35 
 
Our study suggests the feasibility of collecting of economic data using diaries to collect data 
on patients’ usage of NHS resources, healthcare visits prescriptions and out-of-pocket 
expenses. The findings suggest potential savings to both the NHS (e.g., £875.08 per patient) 
and the patients (e.g., £60.95 reduction in out-of-pocket expenses). Nevertheless, as this 
was a collection exercise only, an appropriate Health Economics analysis in the definitive 
trial will provide responses in that area as well. 
 
Overall, no major difficulties were identified in the design or implementation of trial 
procedures. For example, the blinding procedures ran as intended, the rates of retention 
and outcome completion (including the 6-month postal assessment) was very good, and 
from a point onwards there was an excellent communication between clinical and research 
teams, which allow smooth recruitment. There was an imbalance between groups in EQ-5D-
5L data, which didn’t affect the success of our study but may need to be considered in 
planning the definitive trial. 
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Designing, setting up and managing a definitive, multi-centre study has other challenges 
besides recruitment rate, data collection and exercise delivery. One important issue is the 
recruitment of a sufficient number of sites which will: a) deliver the required number of 
participants, b) have experienced clinicians to act as local Principal Investigators, c) have 
dedicated tissue viability services, which will support and promote the study and d) have a 
good communication level between exercise deliverers, tissue viability clinics, local 
stakeholders (e.g., NHS Trusts) and the main research team.  It is therefore, advisable that a 
cost-effective use of a clinical trials unit is implemented, which would safeguard data quality 
and guarantee database management, in addition to costing dedicated personnel (e.g., a 
trial co-ordinator and a trial manager) for day-to-day study management and involving 
experienced research sites in previous, similar studies (which would safeguard a consistent 
delivery of the trial protocol). 
 
Our findings support the feasibility and acceptability of both the supervised exercise 
programme in conjunction with compression therapy and the study procedures and all our 
originally-set, success criteria5 were met. In addition, our results suggest that there may be 
significant potential benefit in healing rates and that, if this were confirmed in a full trial, the 
introduction of supervised exercise for VLU may well also be cost-saving for the NHS.  The 
next step will be the design and implementation of an appropriately-powered, multi-centre 
trial is required to provide answers on the clinical and cost-effectiveness of the intervention, 
and measure its impact. 
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Figure Legends  
Figure 1. The flow of participants through the trial. 
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Inclusion Criteria Exclusion Criteria 
Patients who:  
 are at least 18 years of age 
 have at least one venous leg ulcer of 
primarily venous aetiology 
(determined by a clinician) with a 
maximum diameter of at least 1 cm 
 have an ankle brachial pressure index 
(ABPI) of at least 0.8 (recorded within 
the previous 3 months) 
 are able and willing to tolerate lower-
limb compression. 
 
Patients who: 
 are unsuitable or unable to exercise 
(determined by a clinician) 
 are unable or unwilling to tolerate 
lower-limb compression 
 have insulin-controlled diabetes 
mellitus 
 are pregnant 
 have coexisting skin conditions, 
vasculitis, deep venous occlusion or 
malignant/atypical ulceration 
 require major surgery 
 have a leg ulcer with a maximum 
diameter of less than 1 cm 
 have had an ulcer at the same site 
within the previous 3 months 
 are unable or do not wish to consent 
to participation in the trial. 
 
Table 1: Study inclusion and exclusion criteria. 
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Criterion 
 An appropriate primary outcome 
variable is defined. 
 At least 67 % of randomly assigned 
patients in the exercise group are 
compliant with the intervention (defined 
as at least 75 % of the scheduled sessions 
are completed as planned). 
 Loss to follow-up at 12 months is less 
than 20%. 
 Patient preferences are not so strong 
that they result in the conclusion that a 
randomised controlled trial is not a 
feasible design. 
Table 2: Criteria for success/progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Methodological issues Findings Evidence 
What factors influenced 
eligibility and what 
proportion of those 
screened were eligible? 
 
Tissue Viability Clinics see a 
variety of patient wounds 
the majority of which are not 
ulcers or of venous origin.  
 
109 out of 514 screened 
were eligible. 
The most common reasons 
for non-eligibility being ulcer 
not of venous origin or other 
type of wound present=206. 
The main reasons for non-
consent were mainly of 
social origin (e.g., work 
commitments or difficulty 
travelling; n=52). 
Was recruitment successful? Recruitment was slower than 
anticipated 
39 participants were 
recruited within a 21-month 
period 
Were eligible patients 
recruited? 
Conversion rate to 
recruitment was within our 
primary targets. 
39 out of the 109 (36%) 
eligible participants were 
recruited in the study. 
Were participants 
successfully randomised 
and did randomisation yield 
equality in groups? 
Randomisation process 
worked well. 
Similar sized groups, well-
balanced on 
stratification and most other 
variables; however, quality 
of life scores were higher at 
baseline in exercise group. 
Were blinding procedures 
adequate? 
Blinding of outcome 
assessors and ulcer healing 
assessments worked well.  
Two different assessors were 
used at follow-up sessions. 
No discussions were 
reported between 
participants and assessors on 
their study experience 
during follow-up sessions. 
Assessment of digital ulcer 
photographs was completed 
by a team member unaware 
of the association between 
study id numbers and group 
allocation. 
Did participants adhere 
to the intervention? 
 
We experienced a very high 
attendance rate. 
Overall, 13/18 (72%) of the 
exercise group participants 
attended 100% of the 
scheduled exercise sessions. 
512/648 (79%) of the 
scheduled sessions were 
completed.  
 
Was the intervention 
acceptable to the 
Qualitative and quantitative 
data from exercise 
Out of the 27 participants 
who expressed a preference 
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participants? 
 
participants suggests that 
the intervention was 
acceptable. 
 
for a specific group before 
allocation (12 of the study 
participants didn't express a 
preference), 17 (69% 
amongst those expressing 
preference; 44% amongst all) 
preferred exercise. Patient 
interviews (reported 
elsewhere) have also 
suggested a high degree of 
satisfaction. 
Was the intervention 
safe? 
 
Our preliminary safety data 
appears favourable. 
 
Two non-serious adverse 
events (excess fluid 
discharge from ulcer) were 
noted during the study. No 
bandaging was affected 
during the exercise sessions. 
Were outcome 
assessments completed? 
Outcome completion rates 
were very high. 
See results. 
Was it possible to 
calculate intervention and 
healthcare utilisation 
costs? 
 
Yes. Cost of exercise programme: 
£610.22 per participant 
Total costs per participant 
were £2412.2 (including Out 
of Pocket expenses) and 
£1537.1 for control and 
exercise, respectively. 
Was retention to the 
study good? 
Retention was very high. Retention rate = 95% 
Did all components of 
the protocol work 
together? 
 
From the point that the 
recruitment procedures 
were modified, components 
had strong synergy. 
There were no major 
difficulties identified in the 
various processes and the 
researchers’ ability to 
implement them. For 
example, if participants were 
recruited, there was 
excellent collaboration 
between the care and the 
research team in regards to 
data capture (e.g. tracing, 
ulcer photography). 
Was an appropriate outcome 
defined for the definitive 
trial? 
Yes. Based on our study and 
previous research 
experience, a reduction in 
ulcer healing time appears to 
be the most appropriate 
outcome for the definitive 
trial.  
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Table 3: Summary of trial feasibility and acceptability data. 
 
 
Baseline characteristics Intervention (18) Control (21) Combined (39) 
1. Male gender, n (%)  9/18 (50%)  14/21 (67%)  23/39 (59%) 
2. Age in years, mean (SD)  65.4 (14.9)  61.9,10.9  63.5,12.8 
3. Working, n (%)  8/18 (44%)  6/21 (29%)  14/39 (36%) 
4. White ethnicity, n (%)  17/18 (94%)  21/21 (100%)  38/39 (98%) 
5. Body mass, mean (SD) 102.1 (29.4) 104.9 (24.3) 103.6(26.5) 
6. Blood pressure, heart rate, mean (SD) 
 BP – Systolic (mmHg) 
 BP - Diastolic (mmHg) 
 Heart Rate (beats/minute) 
 
143 (20) 
79 (10) 
72 (13) 
 
140 (18) 
84 (13) 
69 (11) 
 
141 (19) 
81 (12) 
70 (12) 
7. Smoking status, n (%)  4 (22%)  5 (24%)  9 (24%) 
8. Alcohol consumption, units/week, mean 
(SD) 
 8 (13)   9 (14)  8 (13)  
9. Key medications names (% yes) 
Anti-platelet/Anti-coagulant 
Statin 
ACE-inhibitor 
Beta-blocker 
Calcium channel blocker 
Diuretic 
 
7 (39%) 
3 (17%) 
1 (6%) 
3 (17%) 
1 (6%) 
4 (22%) 
 
5 (25%) 
5 (25%) 
1 (5%) 
6 (29%) 
2 (10%) 
3 (15%) 
 
12 (31%) 
8 (21%) 
2 (5%) 
9 (23%) 
3 (8%) 
7 (18%) 
10. Comorbidities, n (%) 
Hypertension 
History of other CVD 
Non-insulin-dependent diabetes 
History of cancer 
Hypercholesterolemia 
12/18 (67%) 
7 (39%) 
1 (6%) 
4 (22%) 
2 (11%) 
1 (6%) 
16/21 (76%) 
4 (20%) 
8 (39%) 
4 (20%) 
1 (5%) 
2 (10%) 
28/39 (72%) 
11 (28%) 
9 (23%) 
8 (21%) 
3 (8%) 
3 (8%) 
Ulcer Related 
1. Had ulcer before, n (%)  11/18 (61%)  14/21 (67%)  25/39 (64%) 
2. Duration of reference ulcer, mean months 
(SD) 
12.7(19.9)  7.1 (8.1)  7.9(14.8) 
3. Time since diagnosis of reference ulcer, 
mean months (SD) 
 8.9(13.7) 6.1(8.0) 7.4(10.9) 
4. Previously had ulcer at same site (>3 
months ago), n(%) 
 3/18 (17%)  3/21 (14%)  6/39 (15%) 
5. Ulcer size, median length in cm(range) 
 median width in cm(range) 
median area in cm2(range) 
2.6(1.2 to 13.5) 
1.9(0.9 to 10.1) 
4.9(1.9 to 136.4) 
2.8(1.2 to 11.8) 
1.9(1.1 to 6.5) 
5.7(1.3 to 56.6) 
2.7(1.2 to 13.5) 
1.9(0.9 to 10.1) 
5.0(1.3 to 136.4) 
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6. ABPI, mean (SD) 1.0(0.1) 1.1(0.2) 1.1(0.2) 
Physical activity and Fitness 
1. Walking with difficulty, n(%) 8/18 (44%) 10/21 (48%) 18/39 (46%) 
2. Walking, n (%): None 
 <1hr 
 1-3hr 
 3+hr 
5 (28%) 
3 (17%)  
6 (33%) 
4 (22%) 
7 (33%) 
5 (24% 
5 (24%) 
4 (19%) 
12 (31%) 
8 (21%) 
11 (28%) 
8 (21%) 
3. Exercise/Physical activity other than 
Walking, n (%) 
 14/18 (78%)  16/21 (76%)  30/39 (77%) 
Table 4: Summary of baseline demographics. 
 
 
 
 
 
 
 
 Exercise Group Control Group 
Test Baseline 
3 
months 
12 
months 
Baseline 
3 
months 
12 
months 
6-minute walk 
distance (m) 
276 (100) 
290 
(123) 
291 
(122) 
280 
(141) 
284 
(138) 
273 
(146) 
Chair sit-to-
stand 
(repetitions) 
8 (4) 10 (4) 
 
9 (4) 9 (4)  9 (4) 
  
8 (4) 
Chair sit-and-
reach (score) 
-6.4 (11.4) 
 2.6 
(16.0) 
2.2 
(11.8) 
-2.8 
(13.6) 
 -0.8 
(11.3) 
-1.7 
(11.9) 
Plantar flexion 
(degrees) 
18.7 (21.0) 
 22 
(15.9) 
17.6 
(12.8) 
15.1 
(9.1) 
 19.0 
(22.3) 
14.7 
(9.4) 
Dorsiflexion 
(degrees) 
20.5 (14) 
 22.9 
(14.8) 
18.9 
(15.8) 
20.3 
(16.5) 
18.7 
(24.2) 
17.4 
(15.3) 
Ankle range of 
movement 
(degrees) 
39.2 (19.9) 
44.9 
(21.3) 
36.6 
(20.8) 
35.4 
(19.7) 
37.7 
(43.2) 
32.1 
(18.9) 
Table 5: Physical fitness/function indices. Data are mean (SD). 
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Table 6: Ulcer related data. 
 
 
 
Table 7: Summary of health status, disease-specific quality of life and pain data (Mean, SD). 
 
 
 
 
 
 Exercise Control 
 
Baseline 3 months 6 
months 
12 
months 
Baseline 3 
months 
6 
months 
12 
months 
Ulcer size  
(Median length 
in cm; range) 
(Median width 
in cm; range) 
(Median area in 
cm2; range) 
2.6(1.2 to 
13.5) 
1.9(0.9 to 
10.1) 
4.9 (1.9 to 
136.4) 
0 (0 to 5) 
0 (0 to 6.5) 
0 (0 to 26) 
 
 
 
 
N/A 
 
 
 
 
 
 
0 (0 to 
5.5) 
0 (0 to 
3.4) 
0 (0 to 
18.7)) 
 
2.8(1.2 to 
11.8) 
1.9(1.1 to 
6.5) 
5.7(1.3 to 
56.6) 
 
1.3 (0 to 
10.2) 
1 (0 to 
7.7) 
1.5 (0 to 
78.5) 
 
N/A 0 (0 to 
14) 
0 (0 to 
10.5) 
0 (0 to 
147) 
Whether healed 
(%) 
                                          53%                       
(9/17) 
65% 
(11/17) 
83%  
(14/17)  
14% 
(3/21) 
40% 
(8/20) 
60% 
(12/20) 
Time of ulcer 
healing (median 
in weeks; range) 
 13  
(3.9 to 
52) 
  
34.7  
(4.3 to 
52) 
Reoccurrence of 
ulcer (%) 
 0%  
(0/17) 
6%  
(1/17) 
12%  
(2/17) 
 
0% 
(0/20) 
12%  
(2/17) 
5%  
(1/19) 
 Exercise Control 
 Baseline 
3 
Months 
6 
Months 
12 
Months 
Baseline 
3 
Months 
6 
Months 
12 
Months 
EQ-5D-5L 
utility score 
 
0.8022 
(0.17) 
 
0.8567 
(0.15) 
 
0.8147 
(0.21) 
 
0.7874 
(0.28) 
0.6010 
(0.35) 
 
0.5698 
(0.42) 
 
0.5740 
(0.40) 
0.5825 
(0.41) 
EQ-VAS 
score 
69.03 
(15.13) 
75.35 
(15.38) 
71.47 
(21.34) 
75.53 
(20.37) 
57.43 
(19.84) 
64.33 
(22.74) 
58.70 
(26.21) 
56.20 
(27.58) 
VEINES-QOL: 
Main 
53.68 
(24.62) 
 
69.53 
(26.13) 
 
67.49 
(27.75) 
 
67.23 
(29.86) 
42.65 
(24.70) 
 
47.24 
(29.57) 
 
51.79 
(33.62) 
52.46 
(34.81) 
VEINES 
symptom 
sub-Domain 
62.03 
(26.52) 
 
 
75.18 
(24.76) 
 
 
73.24 
(26.26) 
 
 
73.41 
(31.73) 
53.17 
(28.82) 
 
 
54.60 
(32.11) 
 
 
58.13 
(30.05) 
58.53 
(33.58) 
Pain score 
24.44 
(27.3) 
15.9 
(27.7) 
16.5 
(28.4) 
7.9 
(22.8) 
30.95 
(31.6) 
22.1 
(32.8) 
28.0 
(36.3) 
30.5 
(36.6) 
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Table 8: Summary of Annual Costs to NHS, Out of Pocket Expenses of Treatment and 
Intervention Study Cost by Group. 
 
Summary of Annual Costs to NHS, Out of Pocket Expenses of Treatment and Exercise Study Cost by Group 
Cost Type Total Per Patient 
Exercise Control Combined Exercise Control Combined 
I. NHS Healthcare professional £12,724.00 £34,573.00 £47,297.00 £748.47 £1,646.33 £1,244.66 
II. A&E £0.00 £2,110.00 £2,110.00 £0.00 £100.48 £55.53 
III. Inpatient Care £0.00 £9,365.00 £9,365.00 £0.00 £445.95 £246.45 
IV. Diagnostic Tests £257.00 £746.00 £1,003.00 £15.12 £35.52 £26.39 
V. Medicine (Free prescriptions) £844.60 £1,476.00 £2,320.60 £49.68 £70.29 £61.07 
Total Cost to NHS £13,825.60 £48,270.00 £62,095.60 £813.27 £2,298.57 £1,634.09 
              
Cost to Patients             
1. Travel £1,081.66 £2,341.68 £3,423.34 £63.63 £111.51 £90.09 
2. Medicine £229.10 £413.44 £642.54 £13.48 £19.69 £16.91 
3. Equipment £621.00 £911.00 £1,532.00 £36.53 £43.38 £40.32 
Total OOP expenses £1,931.76 £3,666.12 £5,597.88 £113.63 £174.58 £147.31 
              
Intervention Study Cost             
1. Exercise intervention 
delivery 
£10,984.00  NA £10,984.00 £610.22       £610.22 
2. Including study Outcome 
measures cost  
£14,051.17 £3,255.17 £17,306.33 £780.62 £155.01 £455.43 
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Enrolment 
Screened for eligibility 
(n=514) 
Ineligible (n=405): 
• Other types of wounds/non venous 
ulcer= 206 
• Venous ulcer not meeting the study 
criteria= 54  
• Patient not suitable for exercise= 85  
•  Other reason (i.e., dementia, other   
mental health problems)= 60 
Invited (n=109) Declined (n=70): 
• Work commitments/inability to 
travel=52 
• Other reasons = 18 
Randomised (n=39) 
Exercise and standard care (n=18) 
• Received exercise (≥1 
sessions, n=18) 
Allocation 
Standard care only (n=21) 
• Received standard care 
(n=21) 
Follow-up 
Lost to follow-up (n=1, 
unwillingness to continue the 
study due to health problems at 
after 3 months’ follow-up) 
 
Lost to follow-up (n=1, 
unwillingness to continue the 
study due to health problems at 
before 3 months’ follow-up) 
Discontinued exercise but 
remained in the study (n=4, one 
due ulcer related problems, three 
due to non-ulcer related health 
problems.  
Analysis 
1. Health-Related QoL (n=17 at 3, 6 and 12 
months) 
2. Senior Fitness test and physical 
functioning/fitness test (n=17 at 3,6 and 12 
months) 
3. Health Economics (n=17 at 3,6 and 12 months) 
4. Clinical data (e.g. ulcer size / healing, ulcer 
recurrence) (n=17 at 3,6 and 12 months) 
1. Health-Related QoL (n=21 at 3 months and n=20 at 6 and 
12 months) 
2. Senior Fitness test and physical functioning/fitness test 
(n=21 at 3 months and n=20 at 6 and 12 months) 
3. Health Economics (n=21 at 3 months and n=20 at 6 and 
12 months) 
4. Clinical data (e.g. ulcer size / healing, ulcer recurrence)  
(n=21 at 3 months and n=20 at 6 and 12 months) 
